The Food and Drug Administration (FDA) has approved Andembry ® (garadacimab-gxii) for prophylactic use to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years ...

The VERONA trial evaluated the safety and efficacy of venetoclax with azacitidine in treatment-naïve adults with higher-risk MDS.

FNP-223 is currently being investigated in a phase 2 trial evaluating the treatment in adults with possible or probable PSP-Richardson syndrome.

Steqeyma is now supplied as a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection, allowing for weight-based dosing for pediatric patients under 60kg.

The former ACIP members are “deeply concerned that these destabilizing decisions may roll back the achievements of US immunization policy.” ...

Heaviest burden born by regions with high sociodemographic index, apart from Japan, which had declining trends.

Similar increases observed for higher-order births; increase in mean age at first birth seen in all racial and ethnic groups.

About half of patients had sustained reduction in depression and anxiety up to two years after psilocybin and psychotherapy.

Largest percentage of emergency department tooth disorder visits accounted for by adults ages 25 to 34 years, White non-Hispanics ...

Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

Pediatricians should provide their patients with their contraceptive of choice, if no medical contraindications exist.

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.